{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:31:55Z","timestamp":1793680315340,"version":"4.5.1"},"reference-count":54,"publisher":"Walter de Gruyter GmbH","issue":"7","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jom-2021-0163_abs_001\">\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The American opioid epidemic has necessitated the search for safe and effective means of treatment for opioid use disorder (OUD). Medication-assisted treatment (MAT) encompasses select medications that are proven effective treatments for OUD. Understanding the mechanisms of action, indications, and implementation of MAT is paramount to increasing its availability to all individuals struggling with opioid addiction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2021-0163_abs_002\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This review is based on an educational series that aims to educate healthcare providers and ancillary healthcare members on the use of MAT for the treatment of OUD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2021-0163_abs_003\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The database PubMed was utilized to retrieve articles discussing the implementation of MAT. Boolean operators and Medical Subject Headings (MeSHs) were applied including: MAT and primary care, MAT and telehealth, methadone, buprenorphine, naltrexone, MAT and osteopathic, MAT and group therapy, and MAT and COVID-19.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2021-0163_abs_004\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three medications have been approved for the treatment of OUD: methadone, naltrexone, and buprenorphine. Identifying ways to better treat and manage OUD and to combat stigmatization are paramount to dismantling barriers that have made treatment less accessible. Studies suggest that primary care providers are well positioned to provide MAT to their patients, particularly in rural settings. However, no study has compared outcomes of different MAT models of care, and more research is required to guide future efforts in expanding the role of MAT in primary care settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2021-0163_abs_005\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The coronavirus disease 2019 (COVID-19) pandemic has led to changes in the way MAT care is managed. Patients require a novel point-of-care approach to obtain care. This review will define the components of MAT, consider the impact of MAT in the primary care setting, and identify barriers to effective MAT. Increasing the availability of MAT treatment will allow for greater access to comprehensive treatment and will set the standard for accessibility of novel OUD treatment in the future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jom-2021-0163","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T06:35:37Z","timestamp":1647239737000},"page":"367-374","source":"Crossref","is-referenced-by-count":21,"title":["Review of medication-assisted treatment for opioid use disorder"],"prefix":"10.1515","volume":"122","author":[{"given":"Nessreen","family":"Ghanem","sequence":"first","affiliation":[{"name":"Neuromusculoskeletal Institute at Rowan University School of Osteopathic Medicine , Stratford , NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Dromgoole","sequence":"additional","affiliation":[{"name":"Neuromusculoskeletal Institute at Rowan University School of Osteopathic Medicine , Stratford , NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Hussein","sequence":"additional","affiliation":[{"name":"Neuromusculoskeletal Institute at Rowan University School of Osteopathic Medicine , Stratford , NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Jermyn","sequence":"additional","affiliation":[{"name":"Neuromusculoskeletal Institute at Rowan University School of Osteopathic Medicine , Stratford , NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2022062216200889322_j_jom-2021-0163_ref_001","doi-asserted-by":"crossref","unstructured":"Cole, ES, DiDomenico, E, Cochran, G, Gordon, AJ, Gellad, WF, Pringle, J, et al.. The role of primary care in improving access to medication-assisted treatment for rural Medicaid enrollees with opioid use disorder. J Gen Intern Med 2019;34:936\u201343, https:\/\/doi.org\/10.1007\/s11606-019-04943-6.","DOI":"10.1007\/s11606-019-04943-6"},{"key":"2022062216200889322_j_jom-2021-0163_ref_002","unstructured":"US Department of Health and Human Services. What is the U.S. opioid epidemic? HHS Gov; 2021. Available from: https:\/\/www.hhs.gov\/opioids\/about-the epidemic\/index.html [Accessed 7 Jan 2022]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_003","unstructured":"Center for Disease Control and Prevention. Opioid data analysis and resources. Department of Health and Human Service; 2020. Available from: https:\/\/www.cdc.gov\/opioids\/data\/analysis-resources.html [Accessed 7 Jan 2022]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_004","unstructured":"Harringa, A. Emergency department visits related to opioid overdoses up significantly during COVID-19 pandemic. Mayo Clinic; 2021. Available from: https:\/\/newsnetwork.mayoclinic.org\/discussion\/emergency-department-visits-related-to-op [Accessed 7 Jan 2022]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_005","doi-asserted-by":"crossref","unstructured":"Luo, F, Li, M, Florence, C. State-level economic costs of opioid use disorder and fatal opioid overdose \u2014 United States, 2017. MMWR Surveill Summ 2021;70. https:\/\/doi.org\/10.15585\/mmwr.mm7015a1.","DOI":"10.15585\/mmwr.mm7015a1"},{"key":"2022062216200889322_j_jom-2021-0163_ref_006","doi-asserted-by":"crossref","unstructured":"Jeffery, MM, D\u2019Onofrio, G, Paek, H, Platts-Mills, TF, Soares, WE, Hoppe, JA. Trends in emergency department visits and hospital admissions in health care systems in 5 states in the first months of the COVID-19 pandemic in the US. JAMA Intern Med 2020;180:1328\u201333, https:\/\/doi.org\/10.1001\/jamainternmed.2020.3288.","DOI":"10.1001\/jamainternmed.2020.3288"},{"key":"2022062216200889322_j_jom-2021-0163_ref_007","unstructured":"Opioid overdose crisis. National Institute on Drug Abuse; 2021. Available from: https:\/\/www.drugabuse.gov\/drug-topics\/opioids\/opioid-overdose-crisis [Accessed 7 Jan 2022]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_008","doi-asserted-by":"crossref","unstructured":"Ober, AJ, Watkins, KE, McCullough, CM, Setodji, CM, Osilla, K, Hunter, SB. Patient predictors of substance use disorder treatment initiation in primary care. J Subst Abuse Treat 2018;90:64\u201372, https:\/\/doi.org\/10.1016\/j.jsat.2018.04.004.","DOI":"10.1016\/j.jsat.2018.04.004"},{"key":"2022062216200889322_j_jom-2021-0163_ref_009","doi-asserted-by":"crossref","unstructured":"Lagisetty, P, Klasa, K, Bush, C, Heisler, M, Chopra, V, Bohnert, A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One 2017;12:e0186315, https:\/\/doi.org\/10.1371\/journal.pone.0186315.","DOI":"10.1371\/journal.pone.0186315"},{"key":"2022062216200889322_j_jom-2021-0163_ref_010","doi-asserted-by":"crossref","unstructured":"Korthuis, PT, McCarty, D, Weimer, M, Bougatsos, C, Blazina, I, Zakher, B, et al.. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med 2017;166:268\u201378, https:\/\/doi.org\/10.7326\/M16-2149.","DOI":"10.7326\/M16-2149"},{"key":"2022062216200889322_j_jom-2021-0163_ref_011","doi-asserted-by":"crossref","unstructured":"Haddad, MS, Zelenev, A, Altice, FL. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health 2015;92:193\u2013213, https:\/\/doi.org\/10.1007\/s11524-014-9924-1.","DOI":"10.1007\/s11524-014-9924-1"},{"key":"2022062216200889322_j_jom-2021-0163_ref_012","doi-asserted-by":"crossref","unstructured":"Roll, D, Spottswood, M, Huang, H. Using shared medical appointments to increase access to buprenorphine treatment. J Am Board Fam Med 2015;28:676\u20137, https:\/\/doi.org\/10.3122\/jabfm.2015.05.150017.","DOI":"10.3122\/jabfm.2015.05.150017"},{"key":"2022062216200889322_j_jom-2021-0163_ref_013","doi-asserted-by":"crossref","unstructured":"Jones, CW, Christman, Z, Smith, CM, Safferman, MR, Salzman, M, Baston, K. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abuse Treat 2018;93:19\u201325, https:\/\/doi.org\/10.1016\/j.jsat.2018.07.008.","DOI":"10.1016\/j.jsat.2018.07.008"},{"key":"2022062216200889322_j_jom-2021-0163_ref_014","doi-asserted-by":"crossref","unstructured":"Kampman, K, Jarvis, M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addiction Med 2015;9:358\u201367, https:\/\/doi.org\/10.1097\/ADM.0000000000000166.","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2022062216200889322_j_jom-2021-0163_ref_015","doi-asserted-by":"crossref","unstructured":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update: erratum. J Addiction Med. 2020;14:267, https:\/\/doi.org\/10.1097\/ADM.0000000000000683.","DOI":"10.1097\/ADM.0000000000000683"},{"key":"2022062216200889322_j_jom-2021-0163_ref_016","doi-asserted-by":"crossref","unstructured":"Mattick, RP, Breen, C, Kimber, J, Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;2009:CD002209, https:\/\/doi.org\/10.1002\/14651858.CD002209.pub2.","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"2022062216200889322_j_jom-2021-0163_ref_017","doi-asserted-by":"crossref","unstructured":"Titus-Lay, EN, Jaynes, HA, Tomaselli Muensterman, E, Walroth, TA, Ott, CA, Desta, Z. Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. Pharmacotherapy 2021;41:238\u201346, https:\/\/doi.org\/10.1002\/phar.2498.","DOI":"10.1002\/phar.2498"},{"key":"2022062216200889322_j_jom-2021-0163_ref_018","doi-asserted-by":"crossref","unstructured":"Treece, JM, Al Madani, M, El Khoury, G, Khraisha, O, Martin, JE, Baumrucker, SJ, et al.. Comprehensive review on methadone induced QT prolongation and torsades. J Pharmacol Pharmacother 2018;9:66\u201375, https:\/\/doi.org\/10.4103\/jpp.JPP_163_17.","DOI":"10.4103\/jpp.JPP_163_17"},{"key":"2022062216200889322_j_jom-2021-0163_ref_019","doi-asserted-by":"crossref","unstructured":"Strain, EC, Bigelow, GE, Liebson, IA, Stitzer, ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281:1000\u20135, https:\/\/doi.org\/10.1001\/jama.281.11.1000.","DOI":"10.1001\/jama.281.11.1000"},{"key":"2022062216200889322_j_jom-2021-0163_ref_020","doi-asserted-by":"crossref","unstructured":"Strain, EC, Stitzer, ML, Liebson, IA, Bigelow, GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993;119:23\u20137, https:\/\/doi.org\/10.7326\/0003-4819-119-1-199307010-00004.","DOI":"10.7326\/0003-4819-119-1-199307010-00004"},{"key":"2022062216200889322_j_jom-2021-0163_ref_021","doi-asserted-by":"crossref","unstructured":"Ma, J, Bao, YP, Wang, RJ, Su, M-F, Liu, M-X, Li, J-Q, et al.. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatr 2019;24:1868\u201383, https:\/\/doi.org\/10.1038\/s41380-018-0094-5.","DOI":"10.1038\/s41380-018-0094-5"},{"key":"2022062216200889322_j_jom-2021-0163_ref_022","unstructured":"Chou, R, Korthuis, TP, Weimer, M, Bougatsos, C, Blazina, I, Zakher, B, et al.. Medication-assisted treatment models of care for opioid use disorder in primary care settings. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016."},{"key":"2022062216200889322_j_jom-2021-0163_ref_023","doi-asserted-by":"crossref","unstructured":"Bell, J, Strang, J. Medication treatment of opioid use disorder. Biol Psychiatr 2020;87:82\u20138, https:\/\/doi.org\/10.1016\/j.biopsych.2019.06.020.","DOI":"10.1016\/j.biopsych.2019.06.020"},{"key":"2022062216200889322_j_jom-2021-0163_ref_024","doi-asserted-by":"crossref","unstructured":"Blum, K, Lott, L, Baron, D, Smith, DE, Badgaiyan, RD, Gold, MS. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. J Syst Integr Neurosci 2020;7, https:\/\/doi.org\/10.15761\/JSIN.100022910.15761\/JSIN.1000229.","DOI":"10.15761\/JSIN.1000229"},{"key":"2022062216200889322_j_jom-2021-0163_ref_025","doi-asserted-by":"crossref","unstructured":"Connery, HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatr 2015;23:63\u201375, https:\/\/doi.org\/10.1097\/HRP.0000000000000075.","DOI":"10.1097\/HRP.0000000000000075"},{"key":"2022062216200889322_j_jom-2021-0163_ref_026","doi-asserted-by":"crossref","unstructured":"Zoorob, R, Kowalchuk, A, Mejia de Grubb, M. Buprenorphine therapy for opioid use disorder. Am Fam Physician 2018;97:313\u201320.","DOI":"10.1001\/jama.2018.7812"},{"key":"2022062216200889322_j_jom-2021-0163_ref_027","unstructured":"Likar, R. Transdermal buprenorphine in the management of persistent pain\u00a0\u2013 safety aspects. Therapeut Clin Risk Manag 2006;2:115\u201325."},{"key":"2022062216200889322_j_jom-2021-0163_ref_028","doi-asserted-by":"crossref","unstructured":"Khanna, IK, Pillarisetti, S. Buprenorphine\u00a0\u2013 an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res 2015;8:859\u201370, https:\/\/doi.org\/10.2147\/JPR.S85951.","DOI":"10.2147\/JPR.S85951"},{"key":"2022062216200889322_j_jom-2021-0163_ref_029","doi-asserted-by":"crossref","unstructured":"Dahan, A, Yassen, A, Romberg, R, Sarton, E, Teppema, L, Olofsen, E, et al.. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627\u201332, https:\/\/doi.org\/10.1093\/bja\/ael051.","DOI":"10.1093\/bja\/ael051"},{"key":"2022062216200889322_j_jom-2021-0163_ref_030","unstructured":"Drug addiction treatment act of 2000. H.R. 2634 ,106th Congress. Congress.gov Library of Congress; 2000. Available from: https:\/\/www.congress.gov\/bill\/106th-congress\/house-bill\/2634."},{"key":"2022062216200889322_j_jom-2021-0163_ref_031","doi-asserted-by":"crossref","unstructured":"Shulman, M, Wai, JM, Nunes, EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs 2019;33:567\u201380, https:\/\/doi.org\/10.1007\/s40263-019-00637-z.","DOI":"10.1007\/s40263-019-00637-z"},{"key":"2022062216200889322_j_jom-2021-0163_ref_032","doi-asserted-by":"crossref","unstructured":"Heo, YA, Scott, LJ. Buprenorphine\/naloxone (Zubsolv\u00ae): a review in opioid dependence. CNS Drugs 2018;32:875\u201382, https:\/\/doi.org\/10.1007\/s40263-018-0560-2.","DOI":"10.1007\/s40263-018-0560-2"},{"key":"2022062216200889322_j_jom-2021-0163_ref_033","doi-asserted-by":"crossref","unstructured":"Cisewski, DH, Santos, C, Koyfman, A, Long, B. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. Am J Emerg Med 2019;37:143\u201350, https:\/\/doi.org\/10.1016\/j.ajem.2018.10.013.","DOI":"10.1016\/j.ajem.2018.10.013"},{"key":"2022062216200889322_j_jom-2021-0163_ref_034","doi-asserted-by":"crossref","unstructured":"Kaucher, KA, Caruso, EH, Sungar, G, Gawenus, L, Hurlbut, K, Sanchez, DC, et al.. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. Am J Emerg Med 2020;38:300\u20134, https:\/\/doi.org\/10.1016\/j.ajem.2019.158373.","DOI":"10.1016\/j.ajem.2019.158373"},{"key":"2022062216200889322_j_jom-2021-0163_ref_035","doi-asserted-by":"crossref","unstructured":"D\u2019Onofrio, G, Chawarski, MC, O\u2019Connor, PG, Pantalon, MV, Busch, SH, Owens, PH, et al.. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med 2017;32:660\u20136, https:\/\/doi.org\/10.1007\/s11606-017-3993-2.","DOI":"10.1007\/s11606-017-3993-2"},{"key":"2022062216200889322_j_jom-2021-0163_ref_036","unstructured":"Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP; 2015 [Online]. Available from: https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/pep15-fedguideotp.pdf [Accessed 10 Dec 2019]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_037","doi-asserted-by":"crossref","unstructured":"Berger, R, Pulido, C, Lacro, J, Groban, S, Robinson, S. Group medication management for buprenorphine\/naloxone in opioid-dependent veterans. J Addiction Med 2014;8:415\u201320, https:\/\/doi.org\/10.1097\/ADM.0000000000000071.","DOI":"10.1097\/ADM.0000000000000071"},{"key":"2022062216200889322_j_jom-2021-0163_ref_038","doi-asserted-by":"crossref","unstructured":"Osilla, KC, Becker, K, Ecola, L, Hurley, B, Manuel, JK, Ober, A, et al.. Study design to evaluate a group-based therapy for support persons of adults on buprenorphine\/naloxone. Addiction Sci Clin Pract 2020;15:25, https:\/\/doi.org\/10.1186\/s13722-020-00199-2.","DOI":"10.1186\/s13722-020-00199-2"},{"key":"2022062216200889322_j_jom-2021-0163_ref_039","doi-asserted-by":"crossref","unstructured":"Sokol, R, LaVertu, AE, Morrill, D, Albanese, C, Schuman-Olivier, Z. Group-based treatment of opioid use disorder with buprenorphine: a systematic review. J Subst Abuse Treat 2018;84:78\u201387, https:\/\/doi.org\/10.1016\/j.jsat.2017.11.003.","DOI":"10.1016\/j.jsat.2017.11.003"},{"key":"2022062216200889322_j_jom-2021-0163_ref_040","doi-asserted-by":"crossref","unstructured":"Hussein, AI, Bekampis, CF, Jermyn, RT. Review of opioid prescribing in the osteopathic and ambulatory setting. J Am Osteopath Assoc 2019;119:820\u201332, https:\/\/doi.org\/10.7556\/jaoa.2019.134.","DOI":"10.7556\/jaoa.2019.134"},{"key":"2022062216200889322_j_jom-2021-0163_ref_041","doi-asserted-by":"crossref","unstructured":"Jerome, JA. An osteopathic approach to chronic pain management. J Am Osteopath Assoc 2017;117:306\u201314, https:\/\/doi.org\/10.7556\/jaoa.2017.056.","DOI":"10.7556\/jaoa.2017.056"},{"key":"2022062216200889322_j_jom-2021-0163_ref_042","doi-asserted-by":"crossref","unstructured":"Licciardone, JC, Minotti, DE, Gatchel, RJ, Kearns, CM, Singh, KP. Osteopathic manual treatment and ultrasound therapy for chronic low back pain: a randomized controlled trial. Ann Fam Med 2013;11:122\u20139, https:\/\/doi.org\/10.1370\/afm.1468.","DOI":"10.1370\/afm.1468"},{"key":"2022062216200889322_j_jom-2021-0163_ref_043","doi-asserted-by":"crossref","unstructured":"Rodondi, PY, Bill, AS, Danon, N, Dubois, J, Pasquier, J, Matthey-de-l\u2019Endroit, F, et al.. Primary care patients\u2019 use of conventional and complementary medicine for chronic low back pain. J Pain Res 2019;12:2101\u201312, https:\/\/doi.org\/10.2147\/JPR.S200375.","DOI":"10.2147\/JPR.S200375"},{"key":"2022062216200889322_j_jom-2021-0163_ref_044","doi-asserted-by":"crossref","unstructured":"Fiellin, DA, O\u2019Connor, PG, Chawarski, M, Schottenfeld, RS. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict 2004;13:S67\u201378, https:\/\/doi.org\/10.1080\/10550490490440843.","DOI":"10.1080\/10550490490440843"},{"key":"2022062216200889322_j_jom-2021-0163_ref_045","doi-asserted-by":"crossref","unstructured":"Weiss, L, Egan, JE, Botsko, M, Netherland, J, Fiellin, DA, Finkelstein, R. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine\/naloxone and HIV treatment. J Acquir Immune Defic Syndr 2011;56:S7\u201313, https:\/\/doi.org\/10.1097\/QAI.0b013e3182097426.","DOI":"10.1097\/QAI.0b013e3182097426"},{"key":"2022062216200889322_j_jom-2021-0163_ref_046","unstructured":"Hussein, A, Jermyn, R. Review of medication-assisted treatment (MAT) for opioid use disorders. Lecture presented at: Rowan University School of Osteopathic Medicine, NeuroMusculoskeletal Institute 2018; Stratford, NJ."},{"key":"2022062216200889322_j_jom-2021-0163_ref_047","unstructured":"Samhsa.gov. COVID-19 public health emergency response and 42 CFR Part 2 guidance [Online]. Available from: https:\/\/www.samhsa.gov\/sites\/default\/files\/covid-19-42-cfr-part-2-guidance-03192020.pdf [Accessed 9 Jul 2021]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_048","unstructured":"Deadiversion.usdoj.gov. How to prescribe controlled substances to patients during the COVID-19 public health emergency; 2020 [Online]. Available from: https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-023)(DEA075)Decision_Tree_(Final)_33120_2007.pdf [Accessed 9 Jul 2021]."},{"key":"2022062216200889322_j_jom-2021-0163_ref_049","doi-asserted-by":"crossref","unstructured":"Wilson, CG, Ramage, M, Fagan, EB. A primary care response to COVID-19 for patients with an opioid use disorder. J Rural Health 2021;37:169\u201371, https:\/\/doi.org\/10.1111\/jrh.12438.","DOI":"10.1111\/jrh.12438"},{"key":"2022062216200889322_j_jom-2021-0163_ref_050","doi-asserted-by":"crossref","unstructured":"Weintraub, E, Greenblatt, AD, Chang, J, Himelhoch, S, Welsh, C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict 2018;27:612\u20137, https:\/\/doi.org\/10.1111\/ajad.12805.","DOI":"10.1111\/ajad.12805"},{"key":"2022062216200889322_j_jom-2021-0163_ref_051","doi-asserted-by":"crossref","unstructured":"Zheng, W, Nickasch, M, Lander, L, Wen, S, Xiao, M, Marshalek, P, et al.. Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2\u00a0year retrospective data analysis. J Addiction Med 2017;11:138\u201344, https:\/\/doi.org\/10.1097\/ADM.0000000000000287.","DOI":"10.1097\/ADM.0000000000000287"},{"key":"2022062216200889322_j_jom-2021-0163_ref_052","doi-asserted-by":"crossref","unstructured":"Samuels, EA, Clark, SA, Wunsch, C, Keeler, LAJ, Reddy, N, Vanjani, R, et al.. Innovation during COVID-19: improving addiction treatment access. J Addiction Med 2020;14:e8\u20139, https:\/\/doi.org\/10.1097\/ADM.0000000000000685.","DOI":"10.1097\/ADM.0000000000000685"},{"key":"2022062216200889322_j_jom-2021-0163_ref_053","doi-asserted-by":"crossref","unstructured":"Volkow, ND, Blanco, C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatr 2021;26:218\u201333, https:\/\/doi.org\/10.1038\/s41380-020-0661-4.","DOI":"10.1038\/s41380-020-0661-4"},{"key":"2022062216200889322_j_jom-2021-0163_ref_054","unstructured":"Home - providers clinical support system: resources for PCPs. Providers clinical support System. 2021 [Online]. Available from: https:\/\/pcssnow.org\/ [Accessed 1 Jul 2021]."}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2021-0163\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2021-0163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T16:21:12Z","timestamp":1655914872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2021-0163\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,6,23]]}},"alternative-id":["10.1515\/jom-2021-0163"],"URL":"https:\/\/doi.org\/10.1515\/jom-2021-0163","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}